Conference Coverage

Immediate postpartum LARC: ‘Agony and ecstasy’


 

EXPERT ANALYSIS FROM ACOG 2019

Immediate postpartum insertion of an intrauterine device (IUD) is highly cost effective despite an expulsion rate of 10%-30%, according to Eve Espey, MD.

“I think [the rate] is going to settle out at around 15%-20%, but good cost-effectiveness studies show that, even if it were that high, it is still highly cost effective,” she said during an update on contraceptives at the annual clinical and scientific meeting of the American College of Obstetricians and Gynecologists.

Immediate postpartum long-acting reversible contraception (LARC), including an IUD or implant, may reduce rapid-repeat pregnancy, she added, noting, however, that while Medicaid is covering it in many states, “it turns out that payment models are very cumbersome; they actually don’t work very well.”

At the University of New Mexico (UNM) in Albuquerque, where Dr .Espey is a professor and chair of the department of obstetrics and gynecology and director of the family planning fellowship, immediate postpartum LARC is offered to women with Medicaid coverage, and payment is received in about 97% of cases.

It took about 4 years of persistent effort to make that happen, she said, adding that the UNM Hospital still is the only one in the state offering the service, although efforts are underway to help other hospitals “troubleshoot the issues.”

Another challenge is the lack of private insurance coverage for immediate postpartum LARC, she said.

“I was super enthusiastic about this a few years ago, and I remain super enthusiastic about it, but I think it’s going to take another 5 years or so [for better coverage], and honestly I think what we really need is an inpatient LARC CPT code to make this happen.”

In this video interview, Dr. Espey discusses the “agony and ecstasy” of immediate postpartum LARC, summarizing the main points regarding its benefits and challenges as presented during an “EdTalk” she gave at the meeting.

Dr. Espey reported having no relevant financial disclosures.

Recommended Reading

FDA expands Essure’s postmarketing surveillance study
MDedge ObGyn
Courts block Trump from eroding contraceptive mandate
MDedge ObGyn
Delayed first contraception use raises unwanted pregnancy risk
MDedge ObGyn
Product Update: Bijuva; Liletta; Aegea Vapor System; Natural Cycles
MDedge ObGyn
Supreme Court halts Louisiana abortion law from taking effect
MDedge ObGyn
Two free contraception apps for providers of family planning
MDedge ObGyn
Your 15-year-old patient requests an IUD without parental knowledge
MDedge ObGyn
Courts temporarily block Title X changes
MDedge ObGyn
Liletta IUD efficacy extends to 6 years
MDedge ObGyn
2019 Update: Contraceptives and unintended pregnancy rates
MDedge ObGyn